INDICATION

1. For the control of clinical signs associated with canine cognitive dysfunction syndrome (CDS). Clinical signs include:

Disorientation
Wanders aimlessly
Appears lost or confused in house or yard
Gets "stuck" in corners or under/behind furniture
Stares into space or at walls
Has difficulty finding the door; stands at hinge side of door
Does not recognize familiar people
Does not respond to verbal cues or name
Appears to forget reason for going outdoorsInteraction with family members

Seeks attention less often
Less likely to stand for petting: walks away while being petted
Less enthusiasm upon greeting
No longer greets family members

Activity and sleep
Sleeps more during the day
Sleeps less during the night
Decrease in purposeful activity
Increase in wandering or pacing
Barks at night for no reason

Housetraining
Urinates indoors
Has accidents indoors soon after being outside
Does not ask to go outside

2. For the control of clinical signs associated with uncomplicated canine pituitary dependent hyperadrenocorticism (PDH) or (Cushing's Disease). Endocrine function testing to confirm PDH should be performed prior to Anipryl administration. Clinical signs include:

Panting
Reduced activity
Increased thirsy
Increased urination
Obesity
Hair loss
Poor skin and hair quality
Decreased responsiveness

CLINICAL USE:

1. CDS is an age-related deterioration of the cognitive abilities characterized by behavioral changes such as disorientation, decreased activity levels and decreased responsiveness. Anipryl was shown to be effective controlling clinical signs after 4 weeks of treatment. Some dogs require up to 3 months to show improvement. However, onset, duration and magnitude of response varied with individual dogs.
2. PDH is an over stimulation of adrenal gland steroid production by an abnormal pituitary gland. The dogs that respond to Anipryl tended to do so with 1-2 months. Duration of response was variable, with some dogs continuing on Anipryl for 1 year with good control of clinical signs and others showing an initial response to therapy only to be followed within several months by recurrence of clinical signs.

SAFETY:

Safety for breeding, pregnant or lactating females has not been determined.  Anipryl is not recommended for other behavioral problems such as aggression.  Anipryl was demonstrated to be safe at the recommended dose range.  Some side effects were salivation, decreased pupillary response, decreased body weight, vomiting, diarrhea, hyperactivity and restlessness.

Periodic patient monitoring to evaluate the response and tolerance to Anipryl and for the presence of concurrent or new disease is recommended.  Visit your veterinarian for more information about this new product.